Erschienen in:
30.05.2020 | Hepatobiliary Tumors
The Landmark Series: Gallbladder Cancer
verfasst von:
Adriana C. Gamboa, MD, MS, Shishir K. Maithel, MD
Erschienen in:
Annals of Surgical Oncology
|
Ausgabe 8/2020
Einloggen, um Zugang zu erhalten
Abstract
Given the rarity of gallbladder carcinoma, level I evidence to guide the multimodal treatment of this disease is lacking. Since 2010, four randomized phase III clinical trials including ABC-02, PRODIGE-12/ACCORD-18, BILCAP, and BCAT, and a single-arm phase II trial (SWOG0809) have been reported on the use of adjuvant strategies for biliary malignancies. These trials have led to the recommendation that patients with resected biliary tract cancer should be offered adjuvant capecitabine chemotherapy and those with R1 margins could be considered for chemoradiotherapy. Because there is no level I evidence to guide neoadjuvant therapy or surgical management, current consensus is based on strong retrospective data. The following review summarizes available trials and highlights the best available evidence that form the basis of consensus statements for the multimodal management of gallbladder carcinoma.